Table 1.
Baseline characteristics according to study group
| Characteristics | Placebo (n=41) | Allopurinol (n=39) |
|---|---|---|
| Age, yr | 58.9±9.3 | 55.9±13.7 |
| Male gender | 32 (78%) | 32 (82%) |
| Race | ||
| White | 34 (83%) | 25 (64%) |
| Black | 5 (12%) | 9 (23%) |
| Other | 2 (5%) | 5 (13%) |
| Hispanic ethnicity | 9 (22%) | 8 (21%) |
| History of smoking | 7 (19%) | 6 (16%) |
| History of DM | 25 (61%) | 23 (61%) |
| History of CVD | 20 (49%) | 16 (41%) |
| BMI, kg/m2 | 32.9±5.7 | 31.7±4.8 |
| SBP, mmHg | 130±16 | 127±14 |
| DBP, mmHg | 77.7±8.6 | 77.4±10.6 |
| HbA1C, % | 6.4±1.4 | 6.6±1.9 |
| Triglycerides, mg/dl | 162±111 | 166±209 |
| LDL-C, mg/dl | 84±23 | 79.5±27 |
| HDL-C, mg/dl | 37.3±8.6 | 38.9±13.8 |
| Creatinine, mg/dl | 1.75±0.42 | 1.81±0.37 |
| CKD-EPI eGFR, ml/min per 1.73m2 | 42.4±9.6 | 41.3±8.9 |
| ACR, mg/g | 452±646 | 374±581 |
| Serum urate levels, mg/dl | 8.7±1.6 | 8.3±1.4 |
| BA-FMD, % Δ | 6.0±5.0 | 4.8±5.0 |
| NMD, % Δ | 19.9±10.8 | 17.6±7.7 |
| Baseline CRP, mg/L | 3.6±3.6 | 5.4±6.7 |
| IL-6, pg/ml | 2.8±3.1 | 4.8±12.9 |
| MCP-1, pg/ml | 169.7±72.3 | 152.0±43.3 |
| Ox-LDL, U/L | 49.3±15.0 | 45.4±11 |
Values are expressed as mean±SD or n (percentage of patients). CVD was defined as history of myocardial infarction, peripheral vascular disease, angina, congestive heart failure, or arrhythmia. SBP, systolic BP; DBP, diastolic BP; LDL-C, LDL cholesterol; HDL-C, HDL cholesterol; ACR, urinary ACR; BA-FMD % Δ, % change in BA-FMD; NMD % Δ, % change in NMD.